News
Novo Nordisk Inks A Major Obesity Deal
Digest more
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrates positive ...
Many are from the most deprived areas, and a significant number are neurodivergent or have other health conditions, a study ...
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...
Explore more
Alabama has moved up the most recent obesity rankings from U.S. News & World Report. And we’re getting awfully close to the ...
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals that 3 to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results